Canada - Engels - Health Canada

mda inc. - linezolid - solution - 2mg - linezolid 2mg - oxazolidinones

Canada - Engels - Health Canada

mda inc. - linezolid - solution - 600mg - linezolid 600mg - oxazolidinones

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - tedizolid phosphate - powder for solution for infusion - 200mg

Verenigd Koninkrijk - Engels - MHRA (Medicines & Healthcare Products Regulatory Agency)

merck sharp & dohme ltd - tedizolid phosphate - tablet - 200mg

Maleisië - Engels - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

merck sharp & dohme (malaysia) sdn bhd - tedizolid phosphate -

Verenigde Staten - Engels - NLM (National Library of Medicine)

merck sharp & dohme llc - tedizolid phosphate (unii: o7drj6r4dw) (tedizolid - unii:97hlq82ngl) - tedizolid phosphate 200 mg - sivextro® is an oxazolidinone-class antibacterial indicated in adult and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (absssi) caused by susceptible isolates of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-resistant [mrsa] and methicillin-susceptible [mssa] isolates), streptococcus pyogenes , streptococcus agalactiae , streptococcus anginosus group (including streptococcus anginosus , streptococcus intermedius , and streptococcus constellatus ), and enterococcus faecalis . to reduce the development of drug-resistant bacteria and maintain the effectiveness of sivextro and other antibacterial drugs, sivextro should be used only to treat absssi that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemio

Verenigde Staten - Engels - NLM (National Library of Medicine)

nabriva therapeutics us, inc. - tedizolid phosphate (unii: o7drj6r4dw) (tedizolid - unii:97hlq82ngl) - sivextro® is an oxazolidinone-class antibacterial indicated in adult and pediatric patients 12 years of age and older for the treatment of acute bacterial skin and skin structure infections (absssi) caused by susceptible isolates of the following gram-positive microorganisms: staphylococcus aureus (including methicillin-resistant [mrsa] and methicillin-susceptible [mssa] isolates), streptococcus pyogenes , streptococcus agalactiae , streptococcus anginosus group (including streptococcus anginosus , streptococcus intermedius , and streptococcus constellatus ), and enterococcus faecalis . to reduce the development of drug-resistant bacteria and maintain the effectiveness of sivextro and other antibacterial drugs, sivextro should be used only to treat absssi that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemio

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

novaguard pty ltd - clomazone - granular formulation - clomazone oxazolidinone active 30.0 g/kg - herbicide - rice | rice - aerial sown | rice - combine sown | rice - sodseeding establishment | combine sown - barnyard or water grass | silver top grass - suppression | barnyard grass | brown beetle grass

Australië - Engels - APVMA (Australian Pesticides and Veterinary Medicines Authority)

fmc australasia pty ltd - clomazone - granular formulation - clomazone oxazolidinone active 30.0 g/kg - herbicide - rice | rice - aerial sown | rice - combine sown | rice - sodseeding establishment | combine sown - barnyard or water grass | silver top grass - suppression | barnyard grass | brown beetle grass

Israël - Engels - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - linezolid - tablets - linezolid 600 mg - linezolid - linezolid - therapy is indicated only when an organism resistant to all other antibiotics is suspected. zyvoxid is indicated in adult and pediatric patients for the treatment of infections when known or suspected to be caused by susceptible organisms including those associated with concurrent bacteraemia such as: 1) pneumonia - community acquired and nosocomial pneumonia including multi drug resistant streptococcus pneumonia (mdrsp). 2) skin and soft tissue infections including diabetic foot infections. 3) enterococcal infections. combination therapy may be indicated if a concomitant gram negative pathogen is documented or suspected.